Ann: Quarterly Update / Appendix 4C, page-162

First para of the quarterly and they can't even get the name of their own reader right.

Life Sciences – engagement with the Therapeutic Goods
Administrator (“TGA”) on achieving regulatory approval for
Eugenie Reader and SARS-CoV-2 Ag Rapid Antigen Test
(“RAT”) and ongoing engagement with Australian industry
and government bodies on the position of Rapid Antigen
testing and domestic manufacturing as well as the
progression of European sales and planning.

Company's reputation shot to bits on almost every level you can think of now. Sales into Europe, imminent TGA approval, recent media exposure that will surely come back to haunt Derek, inability to navigate any regulatory hurdles anywhere. Monumentally disappointing.